Results 151 to 160 of about 18,044 (238)

Anti-VEGF Therapies in Retinal Disorders: Current Landscape and Future Directions. [PDF]

Clin Ophthalmol
Sheth JU.
europepmc   +1 more source

Navigating the Transition: A Scoping Review of System-Level Factors in Biosimilar Integration for Immune-Mediated Inflammatory Diseases. [PDF]

BioDrugs
Kumar S, Dalbeth N, Gasteiger C.
europepmc   +1 more source

Understanding the market dynamics of biosimilars

, 2016
Biosimilars represent an attractive market opportunity in the pharmaceutical industry. In order to understand the underlying market dynamics and to identify the success factors of the biosimilars market, a PEST (political, economic, social, technological)
Dassow, J. (Jonas), Daubenfeld, T. (Thorsten), Keßler, M. (Maximilian), Schulze, J. (Jonas)   +3 more
core  

Biologics and biosimilars medication errors in Saudi Arabia: a nationwide retrospective observational real-world study. [PDF]

Front Med (Lausanne)
Alshammri NT, Alluwaymi WS, Assiri GA, Alshammari TM.   +3 more
europepmc   +1 more source

Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease. [PDF]

Saudi Pharm J
Drweesh H, Alotaibi A, Alqassim HA, Eid MM, Emsaad SA, Saad MO, Higazy AS, Alturaiki A, Almutairi F, Alhussain A, Assiri A, Alkofide H, Alruthia Y, Albassam A, Alsultan A.   +14 more
europepmc   +1 more source

Horizon scan of the clinical development landscape of biosimilar products in the UK and EU. [PDF]

Int J Technol Assess Health Care
Hussain A, Fairbairn R, Khan SK.
europepmc   +1 more source

Non-signaling protein therapeutics: a mechanism-based regulatory framework to modernize biosimilar development and global harmonization. [PDF]

Front Med (Lausanne)
Niazi SK.
europepmc   +1 more source

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars. [PDF]

World J Gastroenterol
Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W, Bernatsky S.   +10 more
europepmc   +1 more source

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab [PDF]

, 2016

core   +1 more source

Effectiveness and safety of adalimumab biosimilar in bio-naive patients with inflammatory bowel disease: a real-life multicenter observational study comparing ABP501, SB5, MSB11022, GP2017, and FKB327. [PDF]

Crohns Colitis 360
Regueiro C, Vázquez Rey MT, Bastón-Rey I, Galego MA, Campos AC, Baz López AM, Arriero GM, Ruiz Barcia MJ, Villaamil PV, EIGA.   +9 more
europepmc   +1 more source